DOCSLIB.ORG

Regulatory Advancements for Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulatory Advancements for Patients 2019 SCIENTIFIC REPORT Regulatory Advancements for Patients REAL-WORLD EVIDENCE: CHARACTERIZING THE USE AND POWER OF REAL-WORLD DATA 11 An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients with Advanced Non-Small-Cell Lung Cancer 26 Validating Real-World Endpoints for an Evolving Regulatory Landscape PATIENT-FOCUSED DRUG DEVELOPMENT: ALIGNING PATIENT NEEDS WITH ONCOLOGY DRUG DEVELOPMENT 45 The Promise of Immuno-oncology: Implications for Defining the Value of Cancer Treatment 56 How Oncologists Perceive the Availability and Quality of Information Generated from Patient-Reported Outcomes (PROs) 64 Improving Attribution of Adverse Events in Oncology Clinical Trials COMPLEX BIOMARKERS: INFORMING DEVELOPMENT AND STANDARDS FOR DIAGNOSTIC TESTS 73 Tumor Mutational Burden Standardization Initiatives: Recommendations for Consistent Tumor Mutational Burden Assessment in Clinical Samples to Guide Immunotherapy Treatment Decisions 84 Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology from Technical Artifacts 97 TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project. 99 Data Generation (and Review Considerations) for Use of a Companion Diagnostic for a Group of Oncology Therapeutic Products OPTIMAL DRUG DEVELOPMENT: ADDRESSING EMERGING OPPORTUNITIES 117 Immuno-Oncology Combination Drug Development for Patients with Disease Progression After Initial Anti-PD-(L)1 Therapy 133 Characterizing the Use of External Controls for Augmenting Randomized Control Arms and Confirming Benefit. 170 Non-small cell lung cancer (NSCLC) case study examining whether results in a randomized control arm are replicated by a synthetic control arm (SCA). 171 Opportunities for Combination Drug Development: Data Sources and Innovative Strategies to Assess Contribution of Components 186 Designing the Future of Cell Therapies INTRODUCTION For more than two decades, Friends of Cancer Research (Friends) has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible. Friends has been successful due to convening the right people at the right time and putting forth revolutionary, yet realistic ideas. Through collaborative and meaningful initiatives, Friends’ programs foster solutions to issues encountered by researchers and regulators as they strive to translate discoveries into safe and effective new treatments. Each year, Friends convenes working groups, hosts scientific conferences, and conducts research on a range of topics to inform regulatory policy, oncology drug development, and clinical practice. These venues are vital to facilitating the creative partnerships and dialogue that ultimately yield many whitepapers, scientific abstracts, and peer-reviewed manuscripts led by Friends that infuse innovative ideas and strategies into the collective science and regulatory landscape. In 2019, we expanded our research portfolio with several large scale pilot projects that are represented in this book. These pilot projects are designed to expand our science un- derstanding as well as inform policy. The 2019 Scientific Report represents Friends’ ongoing mission to drive collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed life-saving treatments to patients. This journal is intended to be a resource for those in the drug development and regulatory space and informative for those interested in science and regulatory issues in oncology. The scientific report contains the full text of the Friends 2019 publications and whitepapers, which focused on several key themes: 1 Real-world evidence: Characterizing the use and power of real-world data 2 Patient-focused drug development: Aligning patient needs with oncology drug development 3 Complex biomarkers: Informing development and standards for diagnostic tests 4 Optimal drug development: Addressing emerging opportunities REAL-WORLD EVIDENCE: CHARACTERIZING THE USE AND POWER OF REAL-WORLD DATA Only 35% of cancer Real-world evidence (RWE) is generated from data collected trials include sicker, from patients receiving routine care. This information is recorded in the patient’s medical record, medical billing and higher risk patients. claims documents, and patient registries. Although the type of Over 60% of RWE gathered varies depending on the source, this data can help researchers gather insights into patient characteristics, cancers occur in treatment patterns, and outcomes of patients treated outside people 65 and older of clinical trials. but only 22% Randomized controlled trials (RCTs) are the gold standard for of clinical trial demonstrating evidence of safety and efficacy in the development of new therapies. While this will always be the case, there may be patients are over 65. opportunities for real-world data (RWD) to provide important sup- plemental information to inform the use of therapies. For example, clinical trials use eligibility criteria to select for specific patient pop- ulations that help maximize the ability to measure treatment effica- cy. While this patient selection can improve the statistical quality of the clinical data, it may not reflect the broader patient population Specific patient that will likely receive the drug in clinical practice. The use of RWD can help assess the use and effectiveness of a therapy in “real- populations world” patients. and characteristics Increasingly, the healthcare community is grasping the capabilities can be collected of RWE and its potential role in facilitating drug development. Congress has also recognized this potential and has included man- from several RWD dates in the 21st Century Cures Act and the Prescription Drug User sources in a similar Fee of 2017 for FDA to explore the use of RWE in prescription drug regulation. The FDA’s Framework for Evaluating RWD/RWE for Use manner to produce in Regulatory Decisions will “evaluate the potential use of RWD to similar results— generate RWE of product effectiveness to help support approval of new indications for drugs… or to help to support or satisfy post this will increase approval study requirements.” confidence in results In response to this growing need, the Friends RWE Pilots 1.0 and from studies with 2.0 were first of their kind efforts that brought together a dozen real-world data. key stakeholders to study RWE for use in drug development and evalutation over time. The collective results of this work are help- ing inform the use of RWD/RWE. 4 friends of cancer research • Specific patient populations and characteristics can be collected from several RWD sources in a similar manner to produce similar RWE PARTNERS results—this will increase confidence in results from studies with real-world data Aetion • Some real-world endpoints correlate to endpoints commonly ASCO CancerLinQ & Concerto used in clinical trials—this suggests that real-world endpoints HealthAI Cancer Research Network could be used as proxies for clinical trial endpoints in real-world COTA data and warrants further investigation FDA Flatiron Health IQVIA™ PUBLICATIONS RELATED TO THIS TOPIC Mayo Clinic • An Exploratory Analysis of Real-World End Points for Assessing Outcomes McKesson Among Immunotherapy-Treated Patients with Advanced Non-Small-Cell Lung NCI SEER-Medicare Linked Cancer (Page 11) Database • Validating Real-World Endpoints for an Evolving Regulatory Landscape OptumLabs® (Page 26) PCORnet Syapse Tempus PATIENT-FOCUSED DRUG DEVELOPMENT: ALIGNING PATIENT NEEDS WITH ONCOLOGY DRUG DEVELOPMENT Patient engagement in research and clinical trials has evolved Some real-world over time. Patients are being actively sought as partners to help design, implement, and disseminate clinical trial findings. It is endpoints correlate estimated that less than 5% of adult cancer patients enroll in a clin- to endpoints ical trial despite many indicating a desire to participate. Engaging patients early and often throughout the entire research and drug commonly used in development process can help inform appropriate trial designs, clinical trials— answer patient relevant questions, and encourage participation. but are difficult to Designing clinical trials that answer questions important to patients measure. This and maximize the information gained are critical. Listening to patients and capturing their experience can help better characterize suggests that the patient’s health, quality of life, and functional status while on a real-world endpoints cancer treatment. Patient reported outcome (PRO) tools are helping better define the value of a treatment and enabling more informed could be used as patient decision-making. proxies for clinical Throughout 2019, Friends helped advance the understanding of endpoints in PRO use in treatment decision making as well as identify key real-world data. recommendations to improve safety monitoring in trials. friends of cancer research 5 • Improved characterization of treatment toxicities and how patients feel and function while on treatment can enable a more Improved character- thorough assessment of a therapy’s benefit and can help prioritize future clinical trials ization of treatment • Mechanisms for more rapid sharing of adverse events toxicities and how information during trials and improved consistency in reporting can help more precisely describe potential patients feel
Load more

Recommended publications
  • UKI NETS 11Th National Conference 25 November 2013 the Royal College of Physicians London, UK
    UKI NETS 11th National Conference 25 November 2013 The Royal College of Physicians London, UK Abstract Marking Panel Alan Anthoney (Leeds, UK) Simon Aylwin (London, UK) Dr Tu Vinh Luong (London, UK) Prakesh Manoharan (Manchester, UK) Nick Reed (Glasgow, UK) UKI NETS would like to thank their sponsors for their kind generosity: Educational Sponsors: Meeting Sponsor: UKI NETS Euro House 22 Apex Court Tel: +44-(0)1454 642277 Woodlands Fax: +44-(0)1454 642222 Bradley Stoke Email: [email protected] Bristol, BS32 4JT, UK Website: www.ukinets.org 2 Contents Pages Programme 4 – 6 Speaker Biographies 7 - 10 Abstracts 12 – 67 3 Programme CPD UKI NETS 11TH NATIONAL CONFERENCE has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 6 category 1 (external) CPD credits. 08:30 Registration, Coffee and Poster viewing 09:25 Welcome and opening remarks Nick Reed (Glasgow, UK) 09:30 – 11:00 Session 1 – Pancreatic NETS –who when and how to intervene? Chair: Graeme Poston 09:30 Imaging assessment of the incidental pancreatic mass Dylan Lewis (London, UK) 09:50 Management of pancreatic primary in presence of metastatic disease Massimo Falconi (Torrette-Ancona, Italy) 10:10 Localisation of insulinoma Karim Meeran (London, UK) 10:30 Surgical approach to the pancreas and parathyroid in patients with MEN1/VHL Barney Harrison (Sheffield, UK) 10:50 Open Floor Q&A 11:00 Coffee, poster viewing and exhibition 11:30 - 12:15 Session 2a – Management dilemmas - Debate – Chemotherapy is first line treatment for pancreatic metastatic
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • Paterson Institute for Cancer Research Scientific Report 2008 Contents
    paterson institute for cancer research scientific report 2008 cover images: Main image supplied by Karim Labib and Alberto sanchez-Diaz (cell cycle Group). Budding yeast cells lacking the inn1 protein are unable to complete cytokinesis. these cells express a fusion of a green fluorescent protein to a marker of the plasma membrane, and have red fluorescent proteins attached to components of the spindle poles and actomyosin ring (sanchez-Diaz et al., nature cell Biology 2008; 10: 395). Additional images: front cover image supplied by Helen rushton, simon Woodcock and Angeliki Malliri (cell signalling Group). the image is of a mitotic spindle in fixed MDcK (Madin-Darby canine kidney) epithelial cells, which have been stained with an anti-beta tubulin antibody (green), DApi (blue) and an anti-centromere antibody (crest, red) which recognises the kinetochores of the chromosomes. the image was taken on the spinning disk confocal microscope using a 150 x lens. rear cover image supplied by Andrei ivanov and tim illidge (targeted therapy Group). Visualisation of tubulin (green) and quadripolar mitosis (DnA stained with DApi), Burkitt’s lymphoma namalwa cell after 10 Gy irradiation. issn 1740-4525 copyright 2008 © cancer research UK Paterson Institute for Cancer Research Scientific Report 2008 Contents 4 Director’s Introduction Researchers’ pages – Paterson Institute for Cancer Research 8 Crispin Miller Applied Computational Biology and Bioinformatics 10 Geoff Margison Carcinogenesis 12 Karim Labib Cell Cycle 14 Iain Hagan Cell Division 16 Nic Jones
    [Show full text]
  • Life Changing Science
    LIFE CHANGING SCIENCE The Francis Crick Institute Annual Review 2017/18 AN INSTITUTE FOR DISCOVERY Our commitment to excellence, our emphasis on multidisciplinary research, our focus on young and emerging talent and our novel ways of partnership working are some of the factors that set the Crick apart. Front cover Vaccinia virus infection (green) disrupts a layer of epithelial cells (red/blue). Courtesy of Michael Way, Group Leader at the Crick. INTRODUCTION 2 Who we are Our year at a glance 2 Introduction by Paul Nurse 4 The Francis Crick Institute is a biomedical Progress against our strategy 6 discovery institute dedicated to understanding the RESEARCH HIGHLIGHTS 10 Cancer-causing mutation fundamental biology underlying health and disease. suppresses immune system 11 Our work is helping to build an understanding of Predicting lung cancer’s return 12 New understanding of human why disease develops and to translate discoveries embryo development 14 Chemical attraction could improve into new ways to prevent, diagnose and treat cancer immunotherapy 16 illnesses such as cancer, heart disease, stroke, Genes linked to malaria parasites’ persistence 17 infections and neurodegenerative diseases. Architecture of our ‘second brain’ 18 Cause of infertility side-stepped in mice 19 Mechanism for spinal cord development discovered 20 A new layer of complexity in embryo development 21 Two DNAs wedded with this ring 22 Unravelling how DNA gets copied 23 Telomerase’s dark side discovered 24 REVIEW OF THE YEAR 26 New group leaders arrive 27 Joined-up thinking 30 Focusing on the molecules of life 32 CryoEM at the Crick 34 Bringing academia and industry closer together 36 The people making research happen 38 Patterns in art and science 40 Rewarding research 42 Appointments 43 Supporting new discoveries 44 Our vision What’s inside Our vision is to be a world- We bring together outstanding scientists Science feature 32 leading multidisciplinary from all disciplines and carry out research Sophisticated microscopy is being biomedical research institute.
    [Show full text]
  • Charles Swanton MRCP Bsc Phd Fibiol
    Charles Swanton MRCP BSc PhD Biography Charles completed the MDPhD programme at University College London in 1999 having gained his PhD from the laboratory of Nic Jones at the Imperial Cancer Research Fund Laboratories establishing the subversion of cell cycle control by the Kaposi’s Sarcoma Herpesvirus encoded K-Cyclin (Swanton et al. Nature 1997) and was awarded the national Pontecorvo Imperial Cancer Research Fund PhD thesis award (Mann et al., 1999; Swanton et al., 1999; Swanton et al., 1997). Charles continued his interest in cell cycle disruption in cancer and its therapeutic applications (Swanton, Lancet Oncology 2004) and was made a Member of the Royal College of Physicians in 2003 and subsequently undertook his medical oncology training at the Royal Marsden Hospital. He was awarded a Cancer Research UK (CR-UK) clinician scientist fellowship in 2004 which allowed him to conduct his post-doctoral research training at the CR-UK London Research Institute with Prof Julian Downward, establishing multi-drug sensitivity mechanisms through RNA interference screening approaches, associated with paclitaxel and other common chemotherapy agents used in oncological practice (Swanton et al., 2007a; Swanton et al., 2007b). These screening datasets resulted in the observation that molecules that mediate chromosomal stability appeared to be significantly associated with those mediating taxane sensitivity and led to the first phase II clinical trial in colorectal cancer to attempt to define prospectively whether tumour chromosomal instability status alters response to a taxane-like drug. In 2008, Charles was awarded an MRC and a CR-UK senior clinical research fellowship and appointed MRC/CR-UK Group leader of the Translational Cancer Therapeutics Laboratory at the CRUK London Research Institute and Fellow of the Society of Biologists (FSB).
    [Show full text]
  • Cancer Research UK Gurdon Institute Prospectus 2020/2021 25 YEARS
    The Wellcome/ Cancer Research UK Gurdon Institute Prospectus 2020/2021 25 YEARS The Wellcome/ Cancer Research UK Gurdon Institute Studying Prospectus 2020/2021 E development to C U G E N D E R E R understand disease C HA R T The Gurdon Institute 3 Contents Welcome Welcome to our new Prospectus, where we highlight our Watermark, the first such award in the University. Special activities for - unusually - two years: 2019 and 2020. The thanks for this achievement go to Hélène Doerflinger, COVID-19 pandemic has made it an extraordinary time Phil Zegerman and Emma Rawlins. Director’s welcome 3 Emma Rawlins 38 for everyone. I want to express my pride and gratitude for the exceptional efforts of Institute members, After incubating Steve Jackson's company Adrestia in About the Institute 4 Daniel St Johnston 40 who have kept our building safe and our research the Institute for two years, we wished them well as they progressing; this applies especially to our core team, moved to the Babraham Research Campus. We also sent COVID stories 6 Ben Simons 42 whose dedication has been key to our best wishes to Meri Huch and our continued progress. As you will Rick Livesey and their labs, as they Highlights in 2019/2020 8 Azim Surani 44 see, there is much to be excited embarked on their new positions in about in our research and activities. Dresden and London, respectively. Focus on research Iva Tchasovnikarova 46 It was terrific to see Gurdon I'm delighted that Emma Rawlins Group leaders Fengzhu Xiong 48 members receive recognition for was promoted to Senior Group their achievements.
    [Show full text]
  • November 2020 | YOUR IMPACT | LORD LEONARD and LADY ESTELLE WOLFSON FOUNDATION NOVEMBER 2020 YOUR IMPACT
    1 | November 2020 | YoUr ImPACT | LorD LEONArD AND LADY eSTeLLe WoLFSoN FoUNDATIoN NOVEMBER 2020 YOUR IMPACT PREPARED FOR THE LORD LEONARD AND LADY ESTELLE WOLFSON FOUNDATION Together we will beat cancer Sir Paul Nurse THANK YOU FOR YOUR SUPPORT Since opening its doors in November 2016, the Crick is establishing its reputation as one of the leading biomedical discovery research institutes in the world. So far, Crick scientists have produced more than 2,500 research publications, which are advancing our fundamental understanding of human health and disease. We are delighted to have your ongoing commitment to support Sir Paul Nurse and his team’s work to understand the intricate processes controlling the cell cycle. Here, we are pleased to present you with an update from Paul and his team in the Cell Cycle Laboratory, as well as a round-up of some of the pioneering advances that the Crick’s researchers have made over the past year. view from the 5th floor of the Francis Crick Institute HIGHLIGHTS AND ACHIEVEMENTS 2,500+ research papers have been published since the Crick opened, sharing new discoveries and AWARDS IN 2020 ideas that could transform the way we approach disease 12 early career group leaders Professor Sir Peter ratcliffe and Professor were appointed this past year, selected Charles Swanton were elected to join the from a pool of 371 applications submitted American Association for Cancer research from across the globe Academy in recognition of their significant The Crick is 5th in the world contributions to innovation and progress
    [Show full text]
  • Donation: the Lifeblood of the NHS
    News from the Medical Research Council Autumn 2018 network Leading science for better health Bl d donation: the lifeblood of the NHS Opinion: How secure data sharing can help us treat dementia Network can also be downloaded as a PDF at: mrc.ukri.org/network CONTENTS News COMMENT FROM Happy birthday to the NHS! 4 Health data: first UK snapshot review 5 Fiona Watt EXECUTIVE CHAIR People As the UK Research and Innovation Royal recognition for Nobel Prize-winner 9 Champion for Talent and Skills, I'm passionate about supporting researchers at the most pivotal points of their careers. It seems clear that we should be investing in Funding the best people, regardless of career stage and geography. £900m for future leaders 15 To help build expertise and opportunities for future careers, we're adding more activities to the list of those eligible to researchers employed on MRC grants, to cover activities that do not directly relate to their Latest discoveries specific research project. Potential therapy identified for common Supporting the career development of research staff is cause of dementia 16 equally important as supporting our researchers. That's why we've introduced a new 'research co-investigator' status for Eye drops with turmeric extract could research staff on MRC grants, to provide recognition for treat common eye disease 17 their intellectual research contributions and to help career development (see page 3). Sharing data and recognising individual research contributions are vital, especially for early-career Features researchers. I'm pleased to see the Dementias Platform UK leading the way with their data portal – a secure platform Blood donation: the lifeblood of the NHS 6 for sharing and analysing dementia research data.
    [Show full text]
  • Predictive Biomarker Discovery Through the Parallel Integration of Clinical Trial and Functional Genomics Datasets
    Swanton et al. Genome Med 2010, 2:53 http://genomemedicine.com/content/2/8/53 CORRESPONDENCE Open Access Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets Charles Swanton1,2*†, James M Larkin2†, Marco Gerlinger1,3†, Aron C Eklund4†, Michael Howell1, Gordon Stamp1,2, Julian Downward1, Martin Gore2, P Andrew Futreal5, Bernard Escudier6, Fabrice Andre6, Laurence Albiges6, Benoit Beuselinck7, Stephane Oudard7, Jens Hoffmann8, Balázs Gyorffy9, Chris J Torrance10, Karen A Boehme11, Hansjuergen Volkmer11, Luisella Toschi12, Barbara Nicke12, Marlene Beck4, Zoltan Szallasi4 Abstract The European Union multi-disciplinary Personalised RNA interference to Enhance the Delivery of Individualised Cytotoxic and Targeted therapeutics (PREDICT) consortium has recently initiated a framework to accelerate the development of predictive biomarkers of individual patient response to anti-cancer agents. The consortium focuses on the identification of reliable predictive biomarkers to approved agents with anti-angiogenic activity for which no reliable predictive biomarkers exist: sunitinib, a multi-targeted tyrosine kinase inhibitor and everolimus, a mam- malian target of rapamycin (mTOR) pathway inhibitor. Through the analysis of tumor tissue derived from pre- operative renal cell carcinoma (RCC) clinical trials, the PREDICT consortium will use established and novel methods to integrate comprehensive tumor-derived genomic data with personalized tumor-derived small hairpin RNA and high-throughput small interfering RNA screens to identify and validate functionally important genomic or transcrip- tomic predictive biomarkers of individual drug response in patients. PREDICT’s approach to predictive biomarker discovery differs from conventional associative learning approaches, which can be susceptible to the detection of chance associations that lead to overestimation of true clinical accuracy.
    [Show full text]
  • Reduced Antibody Cross-Reactivity Following Infection With
    RESEARCH ARTICLE Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains Nikhil Faulkner1,2†, Kevin W Ng1†, Mary Y Wu3†, Ruth Harvey4†, Marios Margaritis5, Stavroula Paraskevopoulou5, Catherine Houlihan5,6, Saira Hussain4,7, Maria Greco7, William Bolland1, Scott Warchal3, Judith Heaney5, Hannah Rickman5, Moria Spyer5,8, Daniel Frampton6, Matthew Byott5, Tulio de Oliveira9,10,11,12, Alex Sigal9,13,14, Svend Kjaer15, Charles Swanton16, Sonia Gandhi17, Rupert Beale18, Steve J Gamblin19, John W McCauley4, Rodney Stuart Daniels4, Michael Howell3, David Bauer7, Eleni Nastouli1,5,8, George Kassiotis1,20* 1Retroviral Immunology, London, United Kingdom; 2National Heart and Lung Institute, Imperial College London, London, United Kingdom; 3High Throughput Screening STP, London, United Kingdom; 4Worldwide Influenza Centre, London, United Kingdom; 5Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom; 6Division of Infection and Immunity, London, United Kingdom; 7RNA Virus Replication Laboratory, London, United Kingdom; 8Department of Population, Policy and Practice, London, United Kingdom; 9School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; 10KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa; 11Centre for the AIDS Programme of Research in South Africa, Durban, South Africa; 12Department of Global Health, University of Washington, Seattle, *For correspondence: United States; 13Africa Health Research
    [Show full text]
  • Consequences of COVID-19 for Cancer Care — a CRUK Perspective
    COMMENT Consequences of COVID-19 for cancer care — a CRUK perspective Emma Greenwood1 and Charles Swanton 1,2,3 ✉ We reflect on the past 10 months of clinical activity in oncology in the UK during the COVID-19 pandemic and suggest how services can be protected during subsequent waves of infection. Since March 2020, the focus for the Government and Understanding how COVID-19 has disrupted diag- A need National Health Service (NHS) of the UK has been on nostic service provision is difficult because the figures remains for a managing the coronavirus disease 2019 (COVID-19) available cover all diagnostic test activity and are not strong clinical pandemic; however, cancer has also remained a high cancer specific. The overall number of individuals priority. How badly have cancer services been affected? receiving or awaiting key cancer diagnostics tests of voice to inform Fortunately, comprehensive data are collected in the endoscopies, CT imaging, non- obstetric ultrasonog- regional, national UK that provide insight into many aspects of cancer raphy and MRI investigations declined in March 2020 and interna- services in a timely manner. Analyses of these data per- (REF.4). In England, ~3.4 million fewer key diagnostic tests tional decision- formed by Cancer Research UK (CRUK) can inform on (–35%) were performed between March and August what happened throughout the peak of the pandemic 2020 compared with the same period in 2019. The making and how well services started to recover. A survey number of individuals receiving these tests has started sent to ~1,800 patients with cancer (all stages) in May to recover since the lowest point in April 2020 but has 2020 provided an early indication of the effect on not returned to pre- pandemic levels.
    [Show full text]
  • Estimated Impact of the COVID-19 Pandemic on Cancer Services and Excess 1
    Open access Original research BMJ Open: first published as 10.1136/bmjopen-2020-043828 on 17 November 2020. Downloaded from Estimated impact of the COVID-19 pandemic on cancer services and excess 1- year mortality in people with cancer and multimorbidity: near real- time data on cancer care, cancer deaths and a population- based cohort study Alvina G Lai ,1,2 Laura Pasea,1,2 Amitava Banerjee ,1,2,3 Geoff Hall,4,5,6 Spiros Denaxas,1,2,7,8 Wai Hoong Chang,1,2 Michail Katsoulis,1 Bryan Williams ,7,9,10 Deenan Pillay,11 Mahdad Noursadeghi,11 David Linch,7,12 Derralynn Hughes,13,14 Martin D Forster,10,13 Clare Turnbull ,15 Natalie K Fitzpatrick,1,2 Kathryn Boyd,16 Graham R Foster,17 Tariq Enver,13 Vahe Nafilyan ,18 Ben Humberstone,18 Richard D Neal,19 Matt Cooper,4,5 Monica Jones,4,5 Kathy Pritchard- Jones,4,20,21,22 Richard Sullivan,23 Charlie Davie,4,14,20 Mark Lawler,4,24 Harry Hemingway 1,2,7 To cite: Lai AG, Pasea L, ABSTRACT Strengths and limitations of this study Banerjee A, et al. Estimated Objectives To estimate the impact of the COVID-19 impact of the COVID-19 pandemic on cancer care services and overall (direct and pandemic on cancer services ► This is the first study that used hospital data and a indirect) excess deaths in people with cancer. and excess 1- year mortality predictive model to dissect and quantify the adverse Methods We employed near real- time weekly data in people with cancer and impact on mortality of the pandemic on patients with multimorbidity: near real- time on cancer care to determine the adverse effect of the cancer and multimorbidity.
    [Show full text]